Zacks Investment Research·Jun 25, 2026
3 AgTech & Food Innovation Stocks Driving Agriculture's FutureBG, DE and NTR are tapping AgTech and food innovation trends through smarter farming, crop nutrition and sustainable food solutions.
Corteva, Inc.(CTVA)Earnings, Financials & Key Ratios
CTVA•NYSE
$86.75
54.2× P/E·Price updated Jul 7, 2026
AboutCorteva, Inc. operates in the agriculture business. It operates through two segments, Seed and Crop Protection. The Seed segment develops and supplies advanced germplasm and traits that produce optimum yield for farms. It offers trait technologies that enhance resistance to weather, disease, insects, and herbicides used to control weeds, as well as food and nutritional characteristics. This segment also provides digital solutions that assist farmer decision-making with a view to optimize product selection, and maximize yield and profitability. The Crop Protection segment offers products that protect against weeds, insects and other pests, and diseases, as well as enhances crop health above and below ground through nitrogen management and seed-applied technologies. This segment provides herbicides, insecticides, nitrogen stabilizers, and pasture and range management herbicides. It serves agricultural input industry. The company operates in the United States, Canada, Latin America, the Asia Pacific, Europe, the Middle East, and Africa. Corteva, Inc. was incorporated in 2018 and is headquartered in Indianapolis, Indiana.Show more
- Revenue$17.4B+2.9%
- EBITDA$3.82B+15.0%
- Net Income$1.09B+20.6%
- EPS (Diluted)1.60+23.1%
- Gross Margin43.59%-0.1%
- EBITDA Margin21.96%+11.8%
- Operating Margin15.05%+21.4%
- Net Margin6.29%+17.2%
- ROE4.52%+22.8%
CTVA Price & Volume
Corteva, Inc. (CTVA) stock price & volume — 10-year historical chart
Loading chart...
Seasonal Cyclicality Masks Underlying Operational Margin Resilience
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Moderate
Financial:Healthy
Cash Flow:Mixed
Primary Risk:Seasonal Commodity Price Sensitivity
Key Thesis Takeaways
- Corteva maintains a resilient capital structure with a debt-to-equity ratio peaking at only 0.23, providing a necessary buffer against the extreme seasonal revenue volatility inherent in its agricultural input business.
- While the company demonstrates consistent R&D investment exceeding $300 million per quarter to sustain its competitive advantage, investors should monitor the $10.4 billion goodwill concentration which may indicate future impairment risks.
- The firm's ability to maintain steady shareholder returns, including $250 million in quarterly buybacks, suggests confidence in long-term liquidity despite significant fluctuations in quarterly net income.
Verdict Logic
while the company maintains a healthy balance sheet with a 0.14 debt-to-equity ratio, the high forward P/E of 22.07 and significant seasonal earnings volatility warrant a cautious wait-and-see approach.
CTVA Growth Metrics
Corteva, Inc. (CTVA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years4.12%
3 Years-0.1%
TTM6.27%
Profit CAGR
10 Years-
5 Years9.94%
3 Years-1.56%
TTM1.93%
EPS CAGR
10 Years-
5 Years11.95%
3 Years0.42%
TTM3.63%
Return on Capital
10 Years3.86%
5 Years6.33%
3 Years7.25%
Last Year8.56%
CTVA Recent Earnings
Corteva, Inc. (CTVA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$1.50+28.2%
$1.17
Rev
$4.9B+5.7%
$4.6B
Q1 2026
Feb 3, 2026Metric
Actual
Est
EPS
$0.22-1.3%
$0.22
Rev
$3.9B-7.8%
$4.2B
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.23+54.6%
$0.51
Rev
$2.6B+6.0%
$2.5B
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$2.20+16.4%
$1.89
Rev
$6.5B+3.0%
$6.3B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $1.50vs $1.17+28.2% | $4.9Bvs $4.6B+5.7% |
| Q1 2026 | Feb 3, 2026 | $0.22vs $0.22-1.3% | $3.9Bvs $4.2B-7.8% |
| Q4 2025 | Nov 4, 2025 | $0.23vs $0.51+54.6% | $2.6Bvs $2.5B+6.0% |
| Q3 2025 | Aug 6, 2025 | $2.20vs $1.89+16.4% | $6.5Bvs $6.3B+3.0% |
Based on last 12 quarters of dataView full earnings history →
Latest CTVA News
Recent stock market news and headlines for Corteva, Inc. (CTVA)
Zacks Investment Research·Jun 18, 2026
FMC and Corteva Partner to Expand Access to Rimisoxafen TechnologyFMC's rimisoxafen deal with Corteva aims to expand access to dual-mode herbicide technology for corn and soybean markets across the Americas.
Seeking Alpha·Jun 17, 2026
Corteva, Inc. (CTVA) Presents at 3rd Annual Materials of the Future Conference TranscriptCorteva, Inc. (CTVA) Presents at 3rd Annual Materials of the Future Conference Transcript
PRNewsWire·Jun 16, 2026
FMC Corporation and Corteva Expand Access to Breakthrough Rimisoxafen Herbicide TechnologyStrategic supply and license agreement will accelerate access for North and South American corn and soybean growers PHILADELPHIA and INDIANAPOLIS, June 16, 2026 /PRNewswire/ -- FMC Corporation (NYSE: FMC) and Corteva, Inc. (NYSE: CTVA), two leading global agricultural science and innovation companies, today announced a co-exclusive strategic supply and license agreement that will expand access to FMC's rimisoxafen technology across North and South America corn and soybean markets, adding an important new tool to each company's respective herbicide portfolio. This collaboration will enable more growers across the Americas to control herbicide-resistant weeds, including Amaranthus species – the number one weed resistance challenge globally in soybeans and critical in cross-crop pressure in corn – with this groundbreaking dual mode of action herbicide technology.
Peers Comparison
Key metrics vs top competitors for Corteva, Inc. (CTVA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $86.75 | $58.24B | 54.22 | 2.92% | 6.29% | 4.52% | 0.81% | |
| $11.59 | $1.45B | -0.65 | -18.34% | -72.93% | -82.27% | — | |
| $114.92 | $17.65B | 12.81 | 19.34% | 23.73% | 22.29% | — | |
| $21.12 | $6.71B | 12.42 | 8.36% | 6.03% | 5.85% | — | |
| $65.32 | $31.43B | 13.78 | 5.33% | 8.6% | 9.47% | — | |
| $368.10 | $198.66B | 25.87 | 9.92% | 20.95% | 89.41% | — |
Compare CTVA vs Peers
Corteva, Inc. (CTVA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CTVA SEC Filings & Documents
Corteva, Inc. (CTVA) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
May 1, 2026·SEC
Material company update
Apr 14, 2026·SEC
10-K Annual Reports
310-Q Quarterly Reports
6Get notified when CTVA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CTVA Frequently Asked Questions
Corteva, Inc. (CTVA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Corteva, Inc.'s revenue?
Corteva, Inc. (CTVA) reported $17.89B in revenue for fiscal year 2025. This represents a 26% increase from $14.24B in 2017.
How fast is Corteva, Inc. growing?
Corteva, Inc. (CTVA) grew revenue by 2.9% over the past year. Growth has been modest.
Is CTVA profitable?
Yes, Corteva, Inc. (CTVA) is profitable, generating $1.16B in net income for fiscal year 2025 (6.3% net margin).
Dividend & Returns
Does CTVA pay dividends?
Yes, Corteva, Inc. (CTVA) pays a dividend with a yield of 0.81%. This makes it attractive for income-focused investors.
What is CTVA's return on equity?
Corteva, Inc. (CTVA) has a return on equity (ROE) of 4.5%. This is below average, suggesting room for improvement.
What is Corteva, Inc.'s free cash flow?
Corteva, Inc. (CTVA) generated $2.05B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.